Sirotnak FM - Search Results

1

Synthesis and antifolate properties of 5,10-ethano-5,10-dideazaaminopterin.

DeGraw JI, Christie PH, Colwell WT, Sirotnak FM. DeGraw JI, et al. Among authors: sirotnak fm. J Med Chem. 1992 Jan 24;35(2):320-4. doi: 10.1021/jm00080a017. J Med Chem. 1992. PMID: 1732549

2

Evidence for the facilitated transport of methotrexate polyglutamates into lysosomes derived from S180 cells. Basic properties and specificity for polyglutamate chain length.

Barrueco JR, Sirotnak FM. Barrueco JR, et al. Among authors: sirotnak fm. J Biol Chem. 1991 Jun 25;266(18):11732-7. J Biol Chem. 1991. PMID: 1711038

3

Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.

Krug LM, Ng KK, Kris MG, Miller VA, Tong W, Heelan RT, Leon L, Leung D, Kelly J, Grant SC, Sirotnak FM. Krug LM, et al. Among authors: sirotnak fm. Clin Cancer Res. 2000 Sep;6(9):3493-8. Clin Cancer Res. 2000. PMID: 10999734 Clinical Trial.

4

A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues. Implications for intrinsic antifolate resistance and directional orientation of the transporter within the plasma membrane of tumor cells.

Roy K, Tolner B, Chiao JH, Sirotnak FM. Roy K, et al. Among authors: sirotnak fm. J Biol Chem. 1998 Jan 30;273(5):2526-31. doi: 10.1074/jbc.273.5.2526. J Biol Chem. 1998. PMID: 9446553

5

Different antifolate-resistant L1210 cell variants with either increased or decreased folylpolyglutamate synthetase gene expression at the level of mRNA transcription.

Roy K, Mitsugi K, Sirlin S, Shane B, Sirotnak FM. Roy K, et al. Among authors: sirotnak fm. J Biol Chem. 1995 Nov 10;270(45):26918-22. doi: 10.1074/jbc.270.45.26918. J Biol Chem. 1995. PMID: 7592937

6

Structural design, biochemical properties, and evidence for improved therapeutic activity of 5-alkyl derivatives of 5-deazaaminopterin and 5-deazamethotrexate compared to methotrexate in murine tumor models.

Sirotnak FM, Schmid FA, Otter GM, Piper JR, Montgomery JA. Sirotnak FM, et al. Cancer Res. 1988 Oct 15;48(20):5686-91. Cancer Res. 1988. PMID: 3167828

7

Further studies on a novel class of genetic variants of the L1210 cell with increased folate analogue transport inward. Transport properties of a new variant, evidence for increased levels of a specific transport protein, and its partial characterization following affinity labeling.

Yang CH, Sirotnak FM, Mines LS. Yang CH, et al. Among authors: sirotnak fm. J Biol Chem. 1988 Jul 15;263(20):9703-9. J Biol Chem. 1988. PMID: 2838477

8

10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties.

Sirotnak FM, Schmid FA, Samuels LL, DeGraw JI. Sirotnak FM, et al. NCI Monogr. 1987;(5):127-31. NCI Monogr. 1987. PMID: 2448650

9

Preferential selection during therapy in vivo by edatrexate compared to methotrexate of resistant L1210 cell variants with decreased folylpolyglutamate synthetase activity.

Rumberger BG, Schmid FA, Otter GM, Sirotnak FM. Rumberger BG, et al. Among authors: sirotnak fm. Cancer Commun. 1990;2(9):305-10. Cancer Commun. 1990. PMID: 2206778

10

Alteration of folate analogue transport inward after induced maturation of HL-60 leukemia cells. Molecular properties of the transporter in an overproducing variant and evidence for down-regulation of its synthesis in maturating cells.

Yang CH, Pain J, Sirotnak FM. Yang CH, et al. Among authors: sirotnak fm. J Biol Chem. 1992 Apr 5;267(10):6628-34. J Biol Chem. 1992. PMID: 1551871

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results